Australia's most trusted
source of pharma news
Wednesday, 08 April 2026
Posted 8 April 2026 PM
Phebra has launched Laceraine, an innovative anaesthetic wound gel, developed and manufactured in Australia.
Laceraine, a combination of lidocaine, tetracaine, and adrenaline, provides localised anaesthesia for superficial open lacerations, where well-tolerated pain relief is essential for wound cleaning and closure in patients, particularly children. The prescription medicine was approved by the TGA just over two years ago.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.